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Abstract The majority of familial Alzheimer’s disease (AD)
cases are linked to mutations on presenilin 1 and 2 genes (PS1
and PS2). The normal function of the proteins and the
mechanisms underlying early-onset AD are currently unknown.
To address this, we screened an expression library for proteins
that bind differentially to the wild-type PS1 and mutant in the
large cytoplasmic loop (PS1L). Thus we isolated the C-terminal
tail of the 170 kDa cytoplasmic linker protein (CLIP-170) and
Reed^Sternberg cells of Hodgkin’s disease-expressed intermedi-
ate filament-associated protein (Restin), cytoplasmic proteins
linking vesicles to the cytoskeleton. PS1L binding to CLIP-170/
restin requires Ca2+. Treating cells with thapsigargin or
ionomycin increased the mutated PS1 in CLIP-170 immunopre-
cipitates. Further, PS1 and CLIP-170 co-localize in transfected
cells and neuronal cultures.
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1. Introduction
All early-onset forms of familial Alzheimer’s disease
(FAD), inherited in an autosomal dominant fashion, are
linked to three gene products: amyloid precursor protein
(APP) [1], presenilin 1 (PS1) [2] and presenilin 2 (PS2) [3].
PS1, which is linked to approximately 50% of all known
early-onset FAD cases, is expressed in somatodendritic pro-
cesses of neurons [4,5]. The genetic and biochemical data from
carriers of these mutations, of which more than 50 have been
identi¢ed so far, suggest that the accelerated pathology and
onset of the disease is caused by a dysfunctional PS1 which
ultimately alters APP proteolytic processing. These conclu-
sions are consistent with the amyloid cascade hypothesis [6].
However, the normal function(s) of PS1 and PS2 in terminally
di¡erentiated neurons, where both are most likely to be ex-
pressed, is currently unknown, as is the e¡ect of the muta-
tions.
A brain expression library was screened for peptides able to
bind to the large cytoplasmic loop of PS1 (PS1L). One of the
clones sustained, in the presence of Ca2, a higher binding
a⁄nity for two FAD-linked mutants (substitutions E280A
and L286V) compared to the wild-type (wt) PS1. This clone
corresponded to the C-terminal tail of 170 kDa cytoplasmic
linker protein (CLIP-170)/Reed^Sternberg cells of Hodgkin’s
disease-expressed intermediate ¢lament-associated protein
(Restin).
2. Materials and methods
2.1. Screening
A single nucleotide (nt) substitution (E280A) was introduced into
PS1 by unique site elimination mutagenesis (Pharmacia). Dr. Bruce
Sopher and Dr. George Martin provided a PS1 cDNA with the
L286V mutation. Dr. Wilma Wasco (Harvard Medical School) pro-
vided a PS2 clone.
Human presenilins (or related fragments) were produced as fusion
proteins to glutathione-S-transferase (GST) [4]. These peptides were
produced in bacteria, transformed with a modi¢ed pGEX-KT vector
[7] containing foreign cDNA in-frame to GST [8]. The GST fusion
peptides, expressed by isopropyl L-D-thiogalactopyranoside (IPTG)
induction, following puri¢cation, were labeled with 32P using casein
kinase II.
Plaques (106) from Y1090 cells infected with a human fetal brain
Vgt11 library (American Tissue Culture Collection #77436) were
IPTG-induced and screened for the expression of L-galactosidase (L-
Gal) fusion proteins that bind speci¢cally to [32P]GST-PS1L (260^407
amino acids (aa) of PS1). Nitrocellulose ¢lters containing an imprint
of the plaques were blocked in Tris-bu¡ered saline (TBS) (50 mM
Tris, 150 mM NaCl, pH 7.4), 3% dry milk powder and 100 Wg
GST/ml. Binding was performed using the probe at a speci¢c activity
of 4U106 counts per minute (cpm)/Wg/ml. Clones that provided 100%
positive plaques after tertiary screening were processed.
2.2. Binding assays
Lysogenized Y1089 cells, infected with candidate clones, were blot-
ted onto nitrocellulose ¢lters as described [9]. Blots were incubated in
TBS containing [32P]peptides (Figs. 1C and 2D). Filters were analyzed
by autoradiography and densitometry.
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Saturation binding curves and Scatchard plots were obtained for
GST-PS1L, GST-PS1L(L280V) and GST-PS1L(E286A) binding to
#22197 fusion protein in the presence of 1 mM Ca2 (total binding)
or 2 mM ethanyldiamino tetraacidic acid (EDTA) (non-speci¢c bind-
ing) [9]. Ca2-dependent binding was the di¡erence.
2.3. Cell cultures
For the transfection of SY5Y cells, PerFect1 Pfx-8 (Invitrogen)
was used. Stably transfected cell-lines were selected in 200 Wg/ml zeo-
cin for pcDNA3.1-Zeo-derived plasmids (Invitrogen) or 1000 Wg/ml
G418 for the pCI-neo-derived plasmids (Promega). Cells were grown
in Dulbecco’s modi¢ed essential medium (DMEM) supplemented with
2 mM L-glutamine, 0.1 mM non-essential aa, 100 IU/ml penicillin,
and 100 Wg/ml streptomycin and 20% fetal calf serum (FCS) in a
5% CO2 incubator.
Neuro-2a cells were similarly grown in DMEM containing 10%
FCS and transfected cell-lines were selected in 600 Wg/ml G418.
Primary neuronal cultures were prepared from rat embryonic cortex
(E16) as described previously [10] and cultured for 3 days in DMEM/
Ham’s F12 medium plus 10% FBS.
2.4. Immuno£uorescent confocal microscopy
Cells were ¢xed (methanol or 2% paraformaldehyde, room temper-
ature, 5 min) then blocked (20 min) in phosphate-bu¡ered saline
(PBS) containing 2% serum or 1% bovine serum albumin (BSA).
For antibody incubations and staining, see Fig. 2 legend. Images
were viewed with the Nikon PCM-2000 confocal microscope.
3. Results
3.1. Screening
Twenty-¢ve clones provided 100% positive plaques upon
tertiary screening using the [32P]GST-PS1L probe. Among
those, 21 were also able to bind to [32P]GST-PS2L, as deter-
mined by dot-blots, and were classi¢ed as non-speci¢c. The
remaining four clones did not bind to [32P]GST-PS2L and
were all sequenced. Here, we describe the characterization of
one of these candidates. Bacteriophage DNA from clone
#22197 contained a 2.4 kb cDNA insert at the unique EcoRI
site (Fig. 1A). Western blotting of lysogenized #22197-in-
fected Y1089 cells, using anti-L-Gal antibodies, showed that
a 170^175 kDa L-Gal fusion protein was expressed (Fig. 1B).
The EcoRI site in Vgt11 is located 53 nt upstream of the L-Gal
termination codon. Since L-Gal is a 116 kDa protein, only
part of the 2.4 kb insert was a reading frame. DNA sequence
analysis [11] determined that 381 nt at the 5P end of the insert
were 100% identical to the 2689^3069 nt fragment of CLIP-
170 (GenBank: M97501) [12] and to the 2838^3218 nt frag-
ment of Restin (EMBL: X64838) [13]. Restriction map anal-
ysis con¢rmed that the insert corresponded to the C-terminal
portion of either CLIP-170 or Restin with an additional 3P
untranslated fragment (results not shown).
CLIP-170 is a 1392 aa microtubule-interacting protein
C
Fig. 1. Characterization of clone #22197. A: #22197 clone contains
2.4 kb insert. Lane 1: pBR322 digested with HinFI. Lane 2: Puri-
¢ed phage DNA from #22197-infected bacteria, digested with
EcoRI and applied to a 1.2% agarose gel. B: #22197 encodes a
170^175 kDa L-Gal fusion protein. Y1089 bacterial cells were in-
fected with Vgt11 (lane 1) and clone #22197 (lanes 2 and 3). Lyso-
gens were either induced by IPTG (lanes 1 and 3) or not (lane 2).
Western blotting was performed using antibodies to L-Gal (Prome-
ga). C: Speci¢city of binding to GST-PS1L; e¡ect of Ca2 and
FAD-linked mutations. Extracts (25 Wg) from lysogens of Y1089
cells infected with the #22197 clone, induced with IPTG, were blot-
ted onto a nitrocellulose ¢lter. Blots were cut, placed in wells of a
microtiter plate and incubated with 32P-labeled GST peptides (x-
axis) in the absence or presence of 2 mM EDTA or 1 mM CaCl2
or excess unlabeled peptides. Each blot was incubated with 4U106
cpm/ml of [32P]peptides (1 Wg/ml) for 1 h. Filters were exposed to
XAR-5 ¢lm (Kodak) overnight. Radioactive signals were quanti¢ed
by densitometry and expressed as a percentage of controls (¢rst
group), set at 100%. D: Saturation curves and Scatchard plots. Ex-
tracts from #22197 lysogens were applied onto nitrocellulose as in
(C), blocked and then incubated with di¡erent amounts of
[32P]GST-PS1L(L286V) in the presence of 1 mM CaCl2 or 2 mM
EDTA. Ca2-dependent binding was determined as the di¡erence.
The amount of bound probe was determined from speci¢c activity.
Kd values were determined from Scatchard plots of the saturation
data (inset). Bound/free (B/F) and bound probe are expressed
as fmol/mg protein per nM and fmol/mg of protein, respectively.
Similar curves were obtained for [32P]GST-PS1L and [32P]GST-
PS1L(E280A) (not shown).
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(MIP) [12] known to link membrane organelles to microtu-
bules [14]. Restin is identical to CLIP-170 except that it con-
tains additional 35 aa (residues 457^491). Restin is overex-
pressed in Reed^Sternberg cells of Hodgkin’s disease and is
believed to be an intermediate ¢lament-associated protein
with a similar function to CLIP-170.
The binding of the probe was abolished only in the presence
of excess unlabeled GST-PS1L (Fig. 1C, ¢fth bar in each
group) and not GST-PS2L (Fig. 1C, fourth bar in each
group). The latter corresponds to a 50 aa segment of PS2,
within the large hydrophilic loop, a non-homologous region
between PS1 and PS2.
The C-terminal domain of CLIP-170/Restin contains a con-
sensus sequence for a metal binding motif, CX2CX3GHX4C
(1373^1386 aa in CLIP-170), conserved among other MIPs;
CLIP-170/Restin, BIK1 and HIV1-GAG [12]. Therefore, the
binding of [32P]GST-PS1L to CLIP-C/Restin-C (carboxyl-ter-
minal fragment of CLIP-170/Restin, respectively) was exam-
ined either in the presence of a metal chelator or excess Ca2.
Inclusion of 1 mM EDTA abolished binding, consistent with
the requirement for a divalent cation (Fig. 1C, second bars in
each group). Both mutant probes (E280A or L286V substitu-
tion) exhibited a stronger autoradiographic signal in the pres-
ence of 1 mM Ca2 (Fig. 1C, third bars of each group). Thus,
it appears that the interaction of PS1L with CLIP-C/Restin-C
requires a metal which can be chelated by EDTA and sub-
stituted by Ca2.
To test this observation, Ca2-dependent saturation curves
of GST-PS1L binding to lysogenized bacterial extracts, in-
fected by #22197, were obtained [9]. The mutant peptides
Fig. 2. PS1 co-localizes with CLIP-170/Restin. Primary neuronal cultures from rat embryo cortex (E16) were ¢xed in paraformaldehyde and
blocked in PBS containing 1% BSA. For PS1 detection, the primary antibody used was as described blow. For CLIP-170, a mouse monoclonal
antibody was used (1:100 dilution) [14]. Staining was performed with Alexa 488-conjugated donkey anti-goat and Alexa 594-conjugated donkey
anti-mouse antibodies. A: PS1. B: CLIP-170. C: PS1/CLIP-170 co-localization in yellow. SY5Y cells were transfected with pSG5-Myc-CLIP-
170. At 24 h post-transfection, the cells were methanol-¢xed, blocked with 2% donkey serum and incubated (1 h) with a⁄nity-puri¢ed goat
anti-PS1 antibodies (AT antibodies, 1:100) and mouse monoclonal anti-Myc antibodies (Invitrogen). Staining was performed with Texas red-
conjugated donkey anti-goat IgG and FITC-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories). D: PS1. E: Myc-
CLIP-170. F: PS1/Myc-CLIP-170 co-localization in yellow.
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had a higher a⁄nity for CLIP-C/Restin-C, as indicated by
lower dissociation constant (Kd) values: Kd(E280A) = 14 nM
and Kd(L286V) = 15 nM (Fig. 1D) compared to Kd(wt) =
25 nM. Kd values were determined by Scatchard plots (insert
in Fig. 1D). The ability of CLIP-C/Restin-C to bind GST-
PS1L in the absence of additional calcium must have been
acquired during the incubation with the blocking solution.
3.2. Co-localization
Overlapping of endogenously expressed PS1 and either the
endogenous CLIP-170/Restin-like and recombinant Myc-
CLIP-170 immuno£uorescent signals was observed in primary
rat neuronal cultures and SY5Y cells, respectively.
In primary neuronal cultures, co-localization of endogenous
PS1 (Fig. 2A) and CLIP-170/Restin (Fig. 2B) and immuno-
£uorescent staining was observed in perinuclear regions and
neuritic extensions (Fig. 2C). The signal for endogenous
CLIP-170/Restin was considerably weaker compared to that
found in the transfected cells (Fig. 2D,E).
PS1-like immunoreactivity in SY5Y cells was predominant
in a perinuclear region. Staining was observed throughout the
cytoplasm and neuritic extensions (not shown) as reported
previously [4]. When these cells were transfected with the
Myc-CLIP-170 cDNA, PS1-like immunoreactivity was organ-
ized throughout the cytoplasm in arrays, resembling a cyto-
skeletal network (Fig. 2D). Staining for Myc-CLIP-170 in
these cells was strong throughout the cytoplasm as tubular
structures (Fig. 2E). The staining for the two proteins over-
lapped at a perinuclear region (Fig. 2F). Additional overlap
was seen near the cell surface (Fig. 2C). The redistribution of
PS1 staining towards cytoskeletal structures upon overexpres-
sion of CLIP-170 is also reminiscent of a possible association
of PS1 with a MIP.
3.3. Co-immunoprecipitations
Co-immunoprecipitations of PS1 with CLIP-170/Restin
were performed using extracts from SY5Y and Neuro-2a cells.
A pSG5 vector containing a Myc-CLIP-170 cDNA insert [15]
was used for transfecting SY5Y or stably transfected Neuro-
2a cells expressing human wt or mutated PS1. The various
anti-PS1 antibodies used were as follows: anti-MNR2 [4],
directed against the PS1L (311^330 aa), recognized promi-
nently a 48 kDa protein in SY5Y (Fig. 3A, lane 1) and trans-
fected Neuro-2a cell extracts (Fig. 3B). PS1 N-terminus-di-
rected antibodies (AT) (South Western Immunology)
directed against the N-terminus of PS1 (14^33 aa) and PS1
C-terminus-directed antibodies (CT) (Santa Cruz) directed
against the C-terminus of PS1 (448^467 aa) detected, in addi-
tion to the full-length protein, lower molecular weight frag-
ments, representing the 30 kDa N-terminal and 16 kDa
C-terminal derivatives of PS1, respectively (Fig. 3A, lanes 2
and 3).
The only PS1 species co-immunoprecipitated with Myc-
CLIP-170 by anti-Myc antibodies was the full-length protein,
as detected by all of the above three antibodies (Fig. 3C, lanes
1^3). Conversely, Myc-CLIP-170 was detected in the immu-
nocomplex obtained using anti-MNR2, AT or CT antibodies
Fig. 3. Co-immunoprecipitation of PS1 with CLIP-170. [Ca2]i and
the E280A/L286V PS1 mutations. A: Western blot analysis of PS1.
Extracts from SY5Y cells were subjected to Western blotting as de-
scribed [4] using the following antibodies: Lane 1, anti-MNR2 anti-
bodies; Lane 2, AT antibodies; Lane 3, CT antibodies (see Section
2). B: Detection of PS1 in Neuro-2a cells transfected with full-
length PS1 cDNA using pCI-neo: Lane 1, transfected cells with un-
modi¢ed vector; lanes 2 and 3, extracts from two individual clones
transfected with vector containing PS1 cDNA. C: Extracts from
SY5Y cells transiently transfected with Myc-CLIP-170 cDNA were
immunoprecipitated with anti-Myc antibodies (Invitrogen) as de-
scribed before [36]. Pellets were further analyzed by Western blot-
ting using the anti-MNR2 antibodies (lanes 1 and 4) or the AT
antibodies (lane 2) or the CT antibodies (lane 3). In lane 4, the
MNR2 antibody was pre-absorbed with GST-PS1L. The anti-PS1
antibodies were radiolabeled with 125I by the chloramine T method.
Blots were developed by autoradiography. D: Extracts as in (C)
were immunoprecipitated with anti-MNR2 (lanes 1 and 4) or AT
antibodies (lane 2) or CT antibodies (lane 3) and analyzed by West-
ern blotting/autoradiography using [125I]anti-Myc antibodies. In con-
trols, GST-PS1 was included in the reaction (lane 4). E: Neuro-2a
cells stably transfected with pCI-neo containing the PS1 cDNA
with the wt sequence (lanes 1 and 2) or with the E280A (lanes 3
and 4) or L286V mutation (lanes 5 and 6) were transiently trans-
fected with pSG5 containing Myc-CLIP-170 cDNA and were sub-
jected to Western blotting using anti-Myc antibodies. Cultures were
treated for 2 h with 0.1% DMSO (lanes 1, 3 and 5) or 1 WM iono-
mycin, 48 h post-transfection with the pSG5-Myc-CLIP-170 cDNA.
F: Extracts from (E) were immunoprecipitated with anti-Myc anti-
bodies, then, PS1 was detected in the pellets by Western blotting us-
ing anti-MNR2 antibodies, as described in (C). PS1 was not de-
tected in Myc immunocomplexes derived from cells that had not
been transfected with pSG5-Myc-CLIP-170 or transfected with un-
modi¢ed pSG5 vector (not shown).
6
FEBS 23093 27-12-99 Cyaan Magenta Geel Zwart
A.A. Johnsingh et al./FEBS Letters 465 (2000) 53^5856
(Fig. 3D). Pre-absorption of the anti-MNR2 antibody with
GST-PS1L prevented co-immunoprecipitation of Myc-CLIP-
170 (Fig. 3D, lane 4) and abolished detection of PS1 by West-
ern blotting (Fig. 3C, lane 4).
3.4. Ca2+ homeostasis and FAD-linked mutations
We investigated whether addition of ionomycin and thap-
sigargin in cell cultures could in£uence the association of mu-
tant PS1 with CLIP-170. Neuro-2a cells stably transfected
with either wt or mutant PS1 cDNA (expressing equivalent
amounts of PS1, Fig. 3B, lanes 2 and 3) were transiently
transfected with Myc-CLIP-170 cDNA. At 48 h post-trans-
fection, cells were treated (2 h) with 0.1% DMSO (vehicle) or
1 WM ionomycin [16]. Myc-CLIP-170 was immunoprecipi-
tated from the cell extracts using anti-Myc antibodies and
PS1 was detected in the immunocomplex as above. A higher
amount of PS1 was detected in ionomycin-treated cells ex-
pressing mutant PS1 (Fig. 3F, lane 4, 225 þ 19%; lane 6,
194 þ 25%, n = 4), compared to wt PS1 (Fig. 3F, lane 2).
The amount of PS1 recovered from vehicle-treated cells
(Fig. 3F, lanes 1, 3 and 5) was averaged and taken as 100%.
The Ca2 ionophore did not alter the cellular levels of PS1
(not shown) and samples were normalized to contain the same
amount of Myc-CLIP-170 (Fig. 3E, lanes 1^6). Comparable
results were obtained with 1 WM thapsigargin (not shown)
which blocks the endoplasmic reticulum (ER) Ca2-ATPase.
4. Discussion
CLIP-170 and Restin most likely derive from the same gene
[17] mapped to chromosome 12 [18] by di¡erential splicing.
They are both cytoplasmic proteins, believed to conjoin mem-
brane organelles to the microtubules [15] and the intermediate
¢laments [13], respectively. Our ¢ndings of the interaction of
PS1 with CLIP-170/Restin imply that PS1 may be involved in
cellular tra⁄cking, in agreement with its homology to SPE-4
[2].
The requirement of Ca2 for the binding of PS1 to CLIP-
170/Restin and the augmented binding of the mutants may be
of physiological signi¢cance, since mechanisms involving sus-
tained increased intracellular Ca2 have been associated with
toxicity [19], increased production of AL [20], direct e¡ect on
cellular proteases [21] and aberrations in the structure and
dynamics of the cytoskeleton [22].
Recent studies have suggested that the normal function of
PS1 is either directly or indirectly linked to Q-secretase (or a
co-factor) necessary for the proteolytic cleavage that generates
the C-terminal end of AL [23^26]. Further, these studies
showed that PS1 is pivotal not only for the proteolytic pro-
cessing of APP, but for the activation of Notch [27] as well.
The data presented here can provide a possible scenario of
PS1’s involvement in APP metabolism (and possibly Notch)
as an anchoring protein of membrane vesicles traveling along
the cytoskeletal network. The interaction of PS1 with either
CLIP-170 or Restin could allow the attachment of vesicles to
the microtubules or intermediate ¢laments (or neuro¢laments
in neurons), respectively.
It has been demonstrated that PS1 co-localizes with the 53
kDa ER-Golgi intermediate compartment protein [28], an
ER-resident protein, also found in the intermediate compart-
ment between ER and Golgi. Others have shown that PS1 is
found in the nuclear membranes and kinetochores [29]. Our
¢ndings of an association of PS1 with CLIP-170/Restin are
consistent with both locations.
It is unknown how all disease-linked mutations, spanning
the entire sequence of PS1, may impose the same phenotypic
alteration via an abnormal PS1/CLIP-170/Restin interaction.
The PS1 binding domain to CLIP-170/Restin may consist of a
number of residues spread throughout the cytoplasmic por-
tions of PS1 or mutations within the transmembrane or lume-
nal portions of PS1 may be linked to disruption of regulatory
mechanisms of the binding or they may distort crucial struc-
tural elements of PS1. For example, a mutation on sterol
regulatory binding protein (SREBP) cleavage activating pro-
tein a¡ects its binding to SREBPs [30] at a site distant from
the binding domain.
PS1 has been found to interact with a number of proteins,
including APP [31], catenins [32], ¢lamin [33], glycogen syn-
thase kinase-3L, tau [34] and Notch [35]. Further studies are
required to determine whether there is interplay among all
these candidates and how this may ultimately a¡ect PS1’s
function and role in AD.
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